Beta Bionics(NASDAQ) BBNX

Beta Bionics, Inc. makes tools for people with diabetes. The main device gives insulin automatically without counting carbs. This helps patients stay healthy with less daily effort.

A Look at the Product Portfolio

• iLet Bionic Pancreas: Automated insulin delivery system for type 1 diabetes that uses body weight to start treatment.
• Single-Use Supplies: Cartridges and infusion sets that users replace every few days; made up 61% of net sales in the first half of 2026.
• Mobile Application: Software that displays glucose levels and trends while saving data securely in the cloud.

Recent Growth and New Alliances

• Partnered with Dexcom and Abbott to link the iLet system with popular glucose sensors.
• Signed a deal with Xeris Pharmaceuticals in 2024 to develop a new glucagon medicine for future systems.
• Started a clinical trial in July 2026 to expand the iLet for use in adults with type 2 diabetes.
• Completed a study in late 2025 to test a system that delivers two different hormones at once.

How the Technology Stands Out

Beta Bionics simplifies care by using math to decide insulin doses every five minutes. This removes the need for complex settings or math that other pumps often require.

Checking the Latest Numbers

• Net sales reached $32.0 million in the three-month period ended June 30, 2026, up 38% year over year.
• Gross margin improved to 59% in the six-month period ended June 30, 2026, up from 53% a year earlier.
• Sales through the pharmacy channel rose to 37% of net sales in the first half of 2026.
• Total cash, cash equivalents, and investments were $225.2 million as of June 30, 2026.
• Market capitalization was $676.0 million according to recent data.

Beta Bionics in Review

Beta Bionics has shifted from a research firm to a commercial company focused on simplifying diabetes care. Its move toward pharmacy sales and new product types shows a focus on making treatment more accessible.